As an innovative, strategic partner company, Haselmeier develops and produces customised, unique systems that are used worldwide.
The quality, reliability, ease-of-use of these high-tech products play a key role in the therapeutic efficiency quality of life for patients.
Haselmeier has been possession of an allowance to manufacture pharmaceuticals since December 2018, which is performed at production site Buchen, Odenwald, in accordance with §13 Medicines Act (Arzneimittelgesetz AMG) or according to Article 40 Directive 2001/83/EC.
Haselmeier can now offer pharmaceutical and biotechnological companies an assembly, labelling, and packaging service.
Haselmeier chief quality officer Konrad Betzler said: “I am pleased that, after extensive preparatory work in close coordination responsible GMP supervisory authority, we have now received the manufacturing permit.”
Haselmeier will in future assemble the cartridges supplied by customers for the respective therapies pens, as well label package combination products. This service also includes the manufacture of batches for stability testing.
The company offers important complete solutions, for example for small and medium-sized series clinical studies for clinical studies, as well as for biotech start-ups.